2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.33 A Comparative Analysis of Outcomes in Patients with Single EGFR Muations for Concurrent Gene Alterations

EP.12A.33 A Comparative Analysis of Outcomes in Patients with Single EGFR Muations for Concurrent Gene Alterations

Pdf Summary

The study examines the differential responses to targeted therapies in patients with non-small cell lung cancer (NSCLC) based on EGFR mutations. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) are administered as initial therapy to improve life quality in patients with EGFR mutation-sensitive NSCLC. The study's aim is to evaluate the effects of concurrent gene alterations along with EGFR mutations on treatment outcomes with EGFR-TKIs.<br /><br />Conducted from January 2019 to June 2023, this multi-center retrospective cohort study involved 109 patients diagnosed with NSCLC, either harboring EGFR 19del or L858R mutations. The study examined the response of these patients to therapies such as gefitinib, erlotinib or afatinib. Patients were categorized into groups with single EGFR mutations and those with concurrent gene alterations.<br /><br />Key findings reveal that patients with a single EGFR mutation showed a more favorable response to treatment compared to those with concurrent gene mutations. The group with single EGFR mutations had a median progression-free survival (PFS) of 15.03 months, significantly longer than the 11.00 months observed in the co-mutation group. Furthermore, presence of PIK3CA and ALK mutations were associated with more favorable outcomes, unlike KRAS, MET, and BRAF mutations which indicated poor prognosis.<br /><br />In conclusion, the study underscores the significance of identifying concurrent gene alterations for targeted therapeutic strategies. This understanding can aid in the inclusion of appropriate patients in clinical trials, potentially leading to more personalized treatment approaches for NSCLC.

Asset Subtitle

Linh Le

Meta Tag

Speaker Linh Le

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

NSCLC

EGFR mutations

EGFR-TKIs

targeted therapies

concurrent gene alterations

progression-free survival

PIK3CA

ALK mutations

personalized treatment

clinical trials